anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Manufacturers of notch filter-based aids for color vision claim that their products can enhance color perception for people with anomalous trichromacy, a form of color vision deficiency (CVD). Anecdotal reports imply that people with CVD can have radically enhanced color vision when using the filters. However, existing empirical research largely focussed on the effect of notch filters on performance on diagnostic tests for CVD has not found that they have any substantial effect. Informed by a model of anomalous trichromatic color vision, we selected stimuli predicted to reveal the effects of EnChroma filters. Using these stimuli, we tested the ability of EnChroma filters to enhance color vision for 10 deuteranomalous trichromats in three experiments: 1. asymmetric color matching between test and control filter conditions, 2. color discrimination measured using four alternative forced-choice, and 3. color appearance measured using dissimilarity ratings to reconstruct subjective color spaces using multidimensional scaling. To investigate potential effects of long-term adaptation or perceptual learning, participants completed all three experiments at two time points, on first exposure to the filters, and after a week of regular use. We found a significant effect of the filters on color matches in the direction predicted by the model at both time points, implying that the filters can enhance the anomalous trichromatic color gamut. However, we found minimal effect of the filters on color discrimination at threshold. We found a significant effect of the filters in enhancing the appearance of colors along the red-green axis at the first time point, and a trend in the same direction at the second time point. Our results provide the first quantitative experimental evidence that notch filters can enhance color perception for anomalous trichromats.
Novel 1-(2-phenyl-2-hydroxyethylamino)-3-phenoxypropan-2-ols of formula I are obtained by reacting a corresponding epoxide or chlorohydrin with a phenoxypropanolamine. During the reaction, the groups R1, R2, R3, R5 and R6 can be protected by a hydrogenolytically cleavable group. Protective groups present are cleaved after the reaction. The symbols in formula I have the meaning given in the patent claim. The compounds of formula I have a cardiovascular action and furthermore have a vascular-dilating, antihypertensive and antiarrhythmic action. <IMAGE>
Background and Purpose: Mishel's Reconceptualized Uncertainty in Illness Theory describes the changed, more positive appraisal of uncertainty over time in a chronic disease. Therefore, Mishel referred to "probabilistic thinking" and "self-organization." The description of these concepts remained highly abstract, limiting the understanding of how change of uncertainty comes about. We aimed to elaborate on this gap and at refining the theory. Methods: We conducted a study consisting of three parts: (a) concept analyses of "probabilistic thinking" and "self-organization," (b) longitudinal qualitative study to investigate uncertainty experience over time, and (c) triangulation of (a) and (b) to develop theoretical propositions. Results: We developed five theoretical propositions in syllogistic form: (a) if persons experience uncertainty, they think probabilistically to assess the existentiality of potential consequences, (b) if they expect existential consequences, they experience uncertainty as a threat, (c) if the existentiality of uncertainty diminishes, then individuals accept uncertainty as an inherent part of illness, (d) if they accept uncertainty, they cognitively reframe it in a positive way in order to promote recovery, and (e) if persons reexperience uncertainty, they reassess the existentiality of potential consequences. Implications for Practice: We propose "health belief" as a mechanism driving "cognitive reframing" to explain the interrelation between uncertainty and a more positive experience. "Existential uncertainty" offers a new perspective on preventing a change in uncertainty experience. The new concepts can provide guidance to take measures to reduce existential uncertainty and promote health beliefs to change the experience of uncertainty from a negative to a more positive one.
G-aenial Universal Flo, GC, Tokyo, Japan (GF) After applying 37% orthophosphoric acid to the enamel of the lesions for 30 seconds and to the dentin for 15 seconds, the acid will be washed with water and then dried with light air. A universal adhesive (G-Premio Bond, GC, Tokyo, Japan) and then the composite will be applied according to the manufacturer's instructions.
A nonaqueous liquid parenterally deliverable pharmaceutical formulation, and more particularly a nonaqueous liquid parenteral Aceclofenac formulation comprising the selective NSAID Aceclofenac, is disclosed. A process of preparing Aceclofenac formulation, the therapeutic dosage form and storage of dose, and the method of treating a subject having a condition or a disorder wherein treatment with NSAID is indicated, are also disclosed. Diclofenac formed by conversion of Aceclofenac is solubilized by the nonaqueous solubilizer(s), which are substantially inert with respect to such conversion. The composition has Aceclofenac salt stabilizing means for inhibiting precipitation of Aceclofenac. The compositions disclosed in the present invention are stable upon storage at room temperature and at refrigerated temperatures. Compositions disclosed in the present invention, whether ready-to-use or requiring dilution prior to administration, can be prepared by inexpensive processes disclosed herein.
The costoclavicular space block technique is a new developed approach of ultrasound-guided infraclavicular brachial plexus block(USG-ICB) in last two years and has not been studied much yet. USG-ICB represents an attractive option for upper-limb surgery at or below the elbow joint with similar success rate and fewer adverse effects compared with ultrasound-guided supraclavicular block. The paracoracoid approach serves as a standard and traditional method for USG-ICB in clinical practice, easy to learn and perform. However, the minimum effective volume(MEV)of this approach has been studied by different investigators with different regional anesthetics or its mixture, and specially, the 95% MEV result of this approach is more than 30ml in all related researches which is still a large volume. According to the investigators' experience in using the costoclavicular space technique for forearm surgery, it usually can get a comparable sensation and motor block effect by no more than 25ml. Recently, there was a clinical randomized control study which compared the costoclavicular and paracoracoid USG-ICB for upper limb surgery using a 35ml-mixture of 1% lidocaine-0.25% bupivacaine with epinephrine 5 ug/ml and came to the conclusions: two groups resulted in similar onset times and no intergroup difference were found in terms of performance time and success rate. However, 35ml is a much larger regional anesthetic volume than what we used in routine brachial plexus block. So, we set this parallel controlled dose-finding trial to work out the MEV with 0.5% ropivacaine of both approaches above for forearm surgery and compare the performance time between them, providing reasonable evidence for clinical choice. Patients enrolled in this study will be assigned to costoclavicular group and paracoracoid group and in each group, the volume of local anesthetic applied to patients start with 30ml, and then decreased by 2.5ml for next patient when the previous block is successful, otherwise increased by 2.5ml when failed,which is also called a staircase up-and-down method usually applied in dose-finding research of nerve block. After certain reflections of the local anesthetic volume sequential line graph, the minimum effective volume could be calculated.
After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of \[La-\] and \[Glucose\].
High molecular weight drugs such as peptides are not well absorbed across biological membranes such as the nasal mucosa. Absorption can be increased if the drug is given together with an absorption enhancing material. However, it has been found that such material can have an irritant effect on the membrane. The invention provides a drug delivery composition for transmucosal delivery comprising a plurality of microspheres and active drug associated with each microsphere, the drug being for systemic delivery and having a maximum molecular weight of 6000 and the composition being substantially free of an enhancer. The microspheres may be starch, gelatin, collagen or dextran. The composition has been found to increase the absorption of drugs, particularly peptides such as insulin, across mucosal membranes. The compositions are suitable for delivery across mucosal surfaces such as the nose, vagina or eye.
This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
The subject matter disclosed herein provides methods for comparing two data sets and generating a report based on the comparing. In one aspect, the method can include accessing an original data set having one or more fields and accessing a revised data having one or more corresponding fields. The original and revised data sets can include original and revised configuration setting, respectively, for one or more medical devices. The method can further include comparing the fields in the revised data set with the fields in the original data set and generating a report based on the comparing. This report can characterize the differences between the fields in the original data set and the revised data set and identify these differences with formatting representative of the difference. The method can further include providing data characterizing the report. Related apparatus, systems, techniques and articles are also described.
PURPOSE:A pack material of a preventing agent for skin roughness containing a perfume in refined SAKE and a puttylike material formed by incorporating SAKE lees with rice bran and wheat flour, and adding water and a small amount of refined SAKE thereto, having permeability, and capable of dissolving deteriorated dirty materials with difficult drying, etc. CONSTITUTION:A cosmetic of a preventing agent for skin roughness containing a perfume, e.g. jasmine or lemon, etc. added to refined SAKE, and having reduced SAKE smell and a puttylike material formed by incorporating SAKE lees with rice bran and wheat flour at (60-70):(10-15):(15-30) volume ratio. The above-mentioned pack material is a rather hard puttylike material having extensibility and further adhesion due to the SAKE lees and releasability due to the rice bran. In use, water and refined SAKE are added to the puttylike material, and the resultant mixture is fully kneaded to pack the face, etc. The pack material has a high specific heat and is capable of exhibiting the covering effect with lasting and moderate wetness. If a suitable perfume is added to the puttylike material and fully kneaded therewith, there is no trouble regarding SAKE smell.
PURPOSE:To provide a bathing agent composition containing a capsule obtained by coating a volatile bathing agent component with a film-forming substance, effective in suppressing the dissipation of the volatile component during production and storage and preventing the corrosion of the capsule material with the above component and the permeation of the component through the capsule. CONSTITUTION:The objective capsule having a diameter of about 50mu-5mm is produced by mixing (A) bathing agent components comprising an oil or fat such as olive oil, magnolia oil, glycerol, etc., and perfumery such as jasmine oil, lemon oil, rose oil, etc., with (B) other additives such as inorganic salts, inorganic acid, crude drugs, pigments, alcohols, polyhydric alcohols, surfactants, etc., according to the required medicinal benefits of the objective agent and coating the obtained mixture with a film-forming substance such as a water-soluble natural polymer (e.g. gelatin) or synthetic polymer (e.g. polyvinyl alcohol) e.g. by the curing and coating process in liquid. EFFECT:Two or more kinds of flavors can be enjoyed by the use of single bath ing agent composition.
A method, apparatus and computer program product are provided to normalize DICOM image data such that normalized images may be efficiently transmitted to client devices and processed thereby. A method may include converting a DICOM image to a normalized image having a different file format, such as JPEG-XR format. The conversion of the DICOM image may include compressing the DICOM image and converting each of a plurality of pixels of the DICOM image to a grayscale pixel format and a color pixel format. The method may also create a set of related images having the different file format based upon the normalized image. The creation of the set of related images may include creating a plurality of images having different pixel dimensions that are smaller than the pixel dimensions of the normalized image. The method may also transform ancillary information related to the DICOM image to a human readable format.
Oxidative stress is associated with tissue dysfunctions that can lead to reduced health. Prior work has shown that oxidative stress contributes to both muscle atrophy and cellular senescence, which is a hallmark of aging that may drive in muscle atrophy and muscle contractile dysfunction. The purpose of the study was to test the hypothesis that cellular senescence contributes to muscle atrophy or weakness. To increase potential senescence in skeletal muscle, we used a model of oxidative stress-induced muscle frailty, the CuZn superoxide dismutase knockout (Sod1KO) mouse. We treated 6-month-old wildtype (WT) and Sod1KO mice with either vehicle or a senolytic treatment of combined dasatinib (5 mg/kg) + quercetin (50 mg/kg) (D + Q) for 3 consecutive days every 15 days. We continued treatment for 7 months and sacrificed the mice at 13 months of age. Treatment with D + Q did not preserve muscle mass, reduce NMJ fragmentation, or alter muscle protein synthesis in Sod1KO mice when compared to the vehicle-treated group. However, we observed an improvement in muscle-specific force generation in Sod1KO mice treated with D + Q when compared to Sod1KO-vehicle mice. Overall, these data suggest that reducing cellular senescence via D + Q is not sufficient to mitigate loss of muscle mass in a mouse model of oxidative stress-induced muscle frailty but may mitigate some aspects of oxidative stress-induced muscle dysfunction.
PROBLEM TO BE SOLVED: To prepare an active-oxygen scavenger having high active-oxygen- scavenging potency and high antioxidative potency, and sparingly having a side-effect on the human body and having safety for the human body by including an extract of seeds (or their husks) of a plant belonging to the geneses Pecan in family Juglandaceae. SOLUTION: This active-oxygen scavenger includes an extract of seeds (or their husks) of a plant belonging to the genus Pecan in family Juglandaceae. The extract is pref. prepared by extraction with a solvent or a mixed solvent selected from the group consisting of water, methanol, ethanol, n-propanol, iso-propanol and acetone. It is pref. that the quantity of the extract added to food is 0.03-2 wt.% based on the total weight when the food is a seasoning such as fermented soybean paste, soy sauce, mayonnaise, or the like and cooking oil such as salad oil, and is 0.02-2 wt.% based on the total weight when the food is other than those above mentioned. The quantity of the extract added to feed is pref. 0.02-2 wt.% based on the total weight.
BACKGROUND: Chronic gouty arthritis, a prevalent metabolic disorder, has prompted interest in the role of diet and lifestyle in its management. This study examines alkaline water as a non-pharmacological adjunct to traditional medicine, hypothesizing its positive effects on uric acid levels and gout symptoms.
METHODS: In this research, 400 chronic arthritis patients from Guangdong Hydropower Hospital (September 2021-September 2023) were randomly assigned to groups receiving varying concentrations of alkaline water alongside conventional Western medicine, or Western medicine alone. A 1-year follow-up involved assessments using visual analogue scales, joint swelling scores, functional assessment scales, and biochemical markers (serum uric acid, creatinine, urea nitrogen) for comprehensive evaluation.
RESULTS: Pain relief: High-concentration alkaline water significantly reduced VAS pain scores posttreatment (P < .05). Joint swelling: Greatest improvement observed in high-concentration group (P < .001). Daily activity capability: Notable enhancements in daily activity scores in experimental groups (P < .05). Range of joint motion: All groups showed significant improvement posttreatment (P < .05). Inflammatory markers: Experimental groups experienced a notable decrease in C-reactive protein, especially in the low concentration group (P < .001). Erythrocyte sedimentation rate decreases were marginal and not statistically significant (P > .05). Interleukin-1β and tumor necrosis factor-α levels significantly decreased, particularly in the low concentration group. Serum uric acid levels: Significant reduction in serum uric acid observed in all alkaline water groups (P < .05), contrasting with the control group.
CONCLUSION: Alkaline water, particularly at high concentrations, effectively alleviated pain, reduced joint swelling, enhanced daily activities, and improved joint motion in chronic gouty arthritis treatment. It significantly reduced key inflammatory markers (C-reactive protein, interleukin-1β, tumor necrosis factor-α) and serum uric acid levels, suggesting its potential as a valuable adjunct in gout management. The limited impact on erythrocyte sedimentation rate warrants further investigation.
The suitability of Fourier transform infrared spectroscopy as a metastasis prognostic tool has not been reported for some cancer types. Our main aim was to show spectroscopic differences between live un-preprocessed cancer cells of different metastatic levels. Spectra of four cancer cell pairs, including colon cancer (SW480, SW620); human melanoma (WM115, WM266.4); murine melanoma (B16F01, B16F10); and breast cancer (MCF7, MDA-MB-231); each pair having the same genetic background, but different metastatic level were analyzed in the regions 1400-1700 cm-1 and 3100-3500 cm-1 using Principal Component Analysis, curve fitting, multifractal dimension and receiver operating characteristic (ROC) curves. The results show spectral markers I1540/I1473, I1652/I1473, [Formula: see text], and multifractal dimension of the spectral images are significantly different for the cells based on their metastatic levels. ROC curve analysis showed good diagnostic performance of the spectral markers in separating cells based on metastatic degree, with areas under the ROC curves having 95% confidence interval lower limits greater than 0.5 for most instances. These spectral features can be important in predicting the probability of metastasis in primary tumors, providing useful guidance for treatment planning. Our markers are effective in differentiating metastatic levels without sample fixation or drying and therefore could be compactible for future use in in-vivo procedures involving spectroscopic cancer diagnosis.
Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
Oxacillin for Injection, USP is a semisynthetic penicillin antibiotic derived from the penicillin nucleus, 6-amino-penicillanic acid. It is the sodium salt in parenteral dosage form. Each Pharmacy Bulk Package bottle of Oxacillin for Injection, USP contains oxacillin sodium monohydrate equivalent to 10 grams of oxacillin. The sodium content is 64 mg [2.8 mEq] per gram oxacillin. The product is buffered with 21 mg dibasic sodium phosphate per gram oxacillin. Oxacillin for Injection, USP is a white to off-white powder filled in clear glass bottles. Dilute solutions are essentially clear and colorless to yellow. 

  


The chemical name of oxacillin sodium is 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-amino]-7-oxo-, monosodium salt, monohydrate, [2S(2α,5α,6β)]-. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The molecular formula of oxacillin sodium is C19H18N3NaO5S•H2O. The molecular weight is 441.44.  
  
A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents of this pharmacy bulk package are intended for use by a pharmacy admixture service for addition to suitable parenteral fluids in the preparation of admixtures for intravenous infusion (see DOSAGE AND ADMINISTRATION, Directions for Proper Use of Pharmacy Bulk Package). FURTHER DILUTION IS REQUIRED. NOT FOR DIRECT INFUSION.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in other studies or to other elosulfase alfa products may be misleading.

All patients treated with Vimizim 2 mg/kg once per week in the placebo-controlled trial developed antidrug antibodies by Week 4. Anti-drug antibody titers were sustained or increased for the duration of Vimizim treatment. Because all patients developed anti-drug antibodies, associations between antibody titers and reductions in treatment effect or the occurrence of anaphylaxis or other hypersensitivity reactions could not be determined.

All patients treated with Vimizim 2 mg/kg once per week tested positive for neutralizing antibodies capable of inhibiting the drug from binding to the mannose-6-phosphate receptor at least once during the trial. Binding to this receptor is required for Vimizim to be taken into cells where it is active. Neutralizing antibody titers were not determined in the patients. Therefore, the possibility of an association between neutralizing antibody titer and treatment effect cannot be assessed.